Hämostaseologie, Inhaltsverzeichnis Hamostaseologie 2017; 37(02): 127-130DOI: 10.5482/HAMO-16-05-0014 Original article Schattauer GmbH Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disordersInterferon-freie Behandlung der Hepatitis-CVirus-Infektion bei Patienten mit einer angeborenen GerinnungsstörungAutor*innen Institutsangaben Johannes Wiegand 1 Klinik für Gastroenterologie und Rheumatologie, Sektion Hepatologie, Universität Leipzig, Germany Ingolf Schiefke 2 Praxis für Gastroenterologie und Hepatologie Johannisplatz Leipzig, Germany 3 Klinik für Gastroenterologie und Hepatologie, Klinikum St. Georg gGmbH, Leipzig, Germany Kerstin Stein 4 Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universität Magdeburg, Germany Thomas Berg 1 Klinik für Gastroenterologie und Rheumatologie, Sektion Hepatologie, Universität Leipzig, Germany Ulrike Kullig 5 Krankenhaus Dresden-Friedrichstadt, 3. Medizinische Klinik, Dresden, Germany Katrin Ende 6 2. Medizinische Klinik, Helios-Klinik Erfurt, Germany Artikel empfehlen Abstract Volltext als PDF herunterladen(opens in new window) Keywords KeywordsSofosbuvir - ledipasvir - daclatasvir - simeprevir - paritaprevir Schlüsselwörter SchlüsselwörterSofosbuvir - Ledipasvir - Daclatasvir - Simeprevir - Paritaprevir Referenzen References 1 Krebs H, Spannagl M, Schramm W. Morbidity and mortality of patients with haemophilia in Germany 2007/2008. Hämostaseologie 2009; 29 (Suppl. 01) S7-S12. 2 Khan MM, Tait RC, Kerr R. et al. Hepatitis C infection and outcomes in the Scottish haemophilia population. Haemophilia 2013; 19: 870-875. 3 Tagliaferri A, Rivolta GF, Iorio A. et al. Mortality and causes of death in Italian persons with haemophilia, 1990–2007. Haemophilia 2010; 16: 437-446. 4 Fransen van de Putte DE, Makris M, Fischer K. et al. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. J Hepatol 2014; 60: 39-45. 5 Zoulim F, Bailly F. New approaches to the management of hepatitis C in haemophilia in 2012. Haemophilia 2012; 18 (Suppl. 04) 28-33. 6 Stedman CA, Hyland RH, Ding X. et al. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia. 2015 doi: 10.1111/hae.12791. 7 Kowdley KV, Gordon SC, Reddy KR. et al. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. N Engl J Med 2014; 370: 1879-1888. 8 Feld JJ, Kowdley KV, Coakley E. et al. Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med 2014; 370: 1594-1603. 9 Sulkowski MS, Gardiner DF, Rodriguez-Torres M. et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221. 10 Lawitz E, Sulkowski MS, Ghalib R. et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765. 11 Terrault N, Zeuzem S, DiBisceglie A. et al. Treatment outcomes with 8, 12 and 24 weeks regimens of ledipasvir/sofosbuvir for the treatment of hepatitis C infection: Analysis of a multicenter prospective observational study. Hepatology 2015; 61 (Suppl. 01) 256A. 12 Hezode C, Colombo M, Spengler U. et al. C-EDGE IBLD: Efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in subjects with chronic hepatitis C virus infection and inherited blood disorders. J Hepatol 2016; 64: S753
